Daniel Bensen - 17 Sep 2021 Form 4 Insider Report for Tyra Biosciences, Inc. (TYRA)

Role: Chief Operating Officer
Signature: s/ John Healy, Attorney-in Fact
Issuer symbol: TYRA
Transactions as of: 17 Sep 2021
Net transactions value: $0
Form type: 4
Filing time: 17 Sep 2021, 16:48:53 UTC
Previous filing: 14 Sep 2021
Next filing: 04 Nov 2021
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	TYRA	Common Stock	Conversion of derivative security		+8,501	+1.6%		527,981	17 Sep 2021	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	TYRA	Series A Preferred Stock	Conversion of derivative security	$0	-3,273	-100%	$0.000000^*	0	17 Sep 2021	Common Stock	8,501		Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	On September 17, 2021, each share of Series A Preferred Stock converted into Common Stock of the Issuer at a ratio of 1-for-2.5974 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date.